Citi Reiterates Neutral Rating on Agilent (A)

Citi analyst Patrick Donnelly reiterated a Neutral rating and $135.00 price target on Agilent (NYSE: A).

The analyst comments "This morning, Alnylam (covered by David Lebowitz) announced positive top-line results from the HELIOS-B study for vutrisiran (Amvuttra) for treatment of ATTR amyloidosis with cardiomyopathy (ATTR-CM), which met primary endpoints. Considering the dataset, Citi’s view is Amvuttra’s label-expansion to ATTR-CM is highly likely. This trial was in focus for Agilent given the NASD business is a key supplier to ALNY (NASD guided to ~$300mn in F24 revenues) with vutrisiran likely to offer upside to numbers given we do not believe non-approved drugs were in Agilent’s framework. While the contribution to Agilent is likely limited in the near term (Citi models ~$65mn of ALNY revenue for vutrisiran ATTR in 2025), it could ramp significantly with our ALNY analyst seeing potential for >$1bn of revenue for vutrisian ATTR in 2028. We see this potentially shifting the sentiment on the NASD business positively after a challenging stretch for the business in recent quarters."

For an analyst ratings summary and ratings history on Agilent click here. For more ratings news on Agilent click here.

Shares of Agilent closed at $133.25 yesterday.

You May Also Be Interested In